SRR3147741
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- OXIDATIVE_PHOSPHORYLATION+0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- INTERFERON_GAMMA_RESPONSE+0.430
- FATTY_ACID_METABOLISM+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- ADIPOGENESIS+0.370
- IL6_JAK_STAT3_SIGNALING+0.360
- XENOBIOTIC_METABOLISM+0.360
- CHOLESTEROL_HOMEOSTASIS+0.340
Top 10 suppressed
- MITOTIC_SPINDLE-0.210
- SPERMATOGENESIS-0.140
- G2M_CHECKPOINT-0.130
- PROTEIN_SECRETION-0.110
- KRAS_SIGNALING_DN-0.100
- TGF_BETA_SIGNALING-0.100
- UV_RESPONSE_DN-0.100
- PI3K_AKT_MTOR_SIGNALING-0.040
- E2F_TARGETS-0.010
- MYOGENESIS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C884FB38-DE5C-48BA-95F1-4ABD2991E833 | — | — | 0.897 |
| 2 | BS_JG9JZTA9 | low-grade glioma | — | 0.872 |
| 3 | 65DAB913-D39C-4AC4-BB1C-10E58914571F | — | — | 0.871 |
| 4 | 5B9D33F5-1B4F-4C06-A73A-CC723C1EF409 | — | — | 0.866 |
| 5 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.859 |
| 6 | SRR1466871 | GTEX | — | 0.858 |
| 7 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.855 |
| 8 | BS_9BJARSX3 | pleomorphic xanthoastrocytoma(PXA) | — | 0.854 |
| 9 | SRR3147740 | — | — | 0.853 |
| 10 | MDT-AP-2001 | Med | Medulloblastoma | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |